Show simple item record

dc.contributor.authorMohammed, Raihan
dc.contributor.authorOpara, Kaesi
dc.contributor.authorLall, Rahul
dc.contributor.authorOjha, Utkarsh
dc.contributor.authorXiang, Jinpo
dc.date.accessioned2021-01-08T17:22:23Z
dc.date.available2021-01-08T17:22:23Z
dc.date.issued2020-01-09
dc.date.submitted2019-01-29
dc.identifier.others13064-020-0138-9
dc.identifier.other138
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/315934
dc.description.abstractAbstract: As humans, we cannot regenerate axons within the central nervous system (CNS), therefore, making any damage to it permanent. This leads to the loss of sensory and motor function below the site of injury and can be crippling to a person’s health. Spontaneous recovery can occur from plastic changes, but it is minimal. The absence of regeneration is due to the inhibitory environment of the CNS as well as the inherent inability of CNS axons to form growth cones. Amongst many factors, one of the major inhibitory signals of the CNS environment is the myelin-associated Nogo pathway. Nogo-A, Nogo-B and Nogo-C (Nogo), stimulate the Nogo receptor, inhibiting neurite outgrowth by causing growth cones to collapse through activation of Rho Kinase (ROCK). Antibodies can be used to target this signalling pathway by binding to Nogo and thus promote the outgrowth of neuronal axons in the CNS. This use of anti-Nogo antibodies has been shown to upregulate CNS regeneration as well as drastically improve sensory and motor function in both rats and primates when coupled with adequate training. Here, we evaluate whether the experimental success of anti-Nogo at improving CNS regeneration can be carried over into the clinical setting to treat spinal cord injuries (SCI) and their symptoms successfully. Furthermore, we also discuss potential methods to improve the current treatment and any developmental obstacles.
dc.languageen
dc.publisherBioMed Central
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectReview
dc.subjectAxon
dc.subjectCNS
dc.subjectRegeneration
dc.subjectMyelin
dc.subjectNogo
dc.titleEvaluating the effectiveness of anti-Nogo treatment in spinal cord injuries
dc.typeArticle
dc.date.updated2021-01-08T17:22:22Z
prism.issueIdentifier1
prism.publicationNameNeural Development
prism.volume15
dc.identifier.doi10.17863/CAM.63045
dcterms.dateAccepted2020-01-05
rioxxterms.versionofrecord10.1186/s13064-020-0138-9
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidMohammed, Raihan [0000-0002-0824-5243]
dc.identifier.eissn1749-8104


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)